OUR PERSPECTIVE

Shortcomings of existing therapies

Current standard of care treatments are ineffective for millions worldwide.

Limited Efficacy

Slow onset – Up to 3 months or more for SSRIs to take full effect
Trial and error – Remission with first selected SSRI occurs only 30% of the time
Low response rate – Only 50% respond within 8 weeks and 33% become treatment-resistant
High relapse rate – Estimated that 40-60% of patients with SUD return to active addiction

Side Effects

Addiction – 10-15% of benzodiazepine users become addicted
Sexual dysfunction – 55% of patients on SSRIs experience sexual dysfunction
Weight gain – Depending on the drug, patients on SSRIs gain on average 16-24lbs over 12 months
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients

Our unique approach

microscope icon

Compounds with prior evidence in humans

To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.

https://www.atai.life/wp-content/uploads/2020/11/home-1b.png
data icon

Enabling platform technologies

Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics.
https://www.atai.life/wp-content/uploads/2020/11/home-2b.png
platform-model icon

First-in-class

Our portfolio includes a number of assets that have the potential to be developed as first-in-class therapeutics. These are programs which include natural products and their derivatives that have not previously been formally developed as drugs, as well as de novo compounds.

https://www.atai.life/wp-content/uploads/2020/11/home-3b.png

Learn more about our approach

OUR MODEL
WHERE WE’RE HEADED

Our technologies drive efficient drug discovery and improved treatment outcomes.

Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics. 

OUR MODEL

News & Insights

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on ATAI.

Email
submit